Your session is about to expire
← Back to Search
Unknown
JAB-8263 for Solid Tumors
Phase 1
Waitlist Available
Research Sponsored by Jacobio Pharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2.5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called JAB-8263 in adults with advanced solid tumors. The drug works by blocking proteins that help cancer cells grow. The goal is to find out how much of the drug can be safely given and how it affects the body.
Eligible Conditions
- Solid Tumors, Adult
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 2.5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2.5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Find Recommended Phase 2 Dose (RP2D) of JAB-8263
Number of participants with dose limiting toxicities
Secondary study objectives
Area under the curve
Cmax
Duration of response ( DOR )
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: JAB-8263Experimental Treatment1 Intervention
Monotherapy, dose escalation
Find a Location
Who is running the clinical trial?
Jacobio Pharmaceuticals Co., Ltd.Lead Sponsor
20 Previous Clinical Trials
2,129 Total Patients Enrolled
Jacobio PharmaceuticalsStudy DirectorJacobio Pharmaceuticals
10 Previous Clinical Trials
1,066 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger